(90 days)
Not Found
No
The document explicitly states "Mentions AI, DNN, or ML: Not Found" and the device description focuses on mechanical components and surgical solutions.
Yes
The device is a joint replacement for the knee, intended to treat conditions like arthritis, avascular necrosis, and deformities, which are therapeutic interventions.
No
The device described is an implant (tibial baseplate) used in joint replacement surgery, not a diagnostic tool. Its purpose is to treat conditions, not to identify or assess them.
No
The device description explicitly states it is a "tibial baseplate implant with accessories (stem extensions and augments) and instruments," which are physical hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, or tissue) to provide information about a person's health.
- Device Description: The description clearly states that this is a tibial baseplate implant used in joint replacement surgery. This is a surgically implanted device, not a device used to test samples outside the body.
- Intended Use: The intended use describes the conditions for which the joint replacement is indicated, all of which relate to physical conditions of the knee joint requiring surgical intervention.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, performing tests on bodily fluids, or providing diagnostic information based on laboratory analysis.
Therefore, this device falls under the category of a surgical implant, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Joint replacement is indicated for patients suffering from disability due to:
- degenerative, post-traumatic or rheumatoid arthritis;
- avascular necrosis of the femoral condyle;
- post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
- moderate valgus, varus, or flexion deformities;
- treatment of fractures that are unmanageable using other techniques.
This device may also be indicated in the salvage of previously failed surgical attempts. All devices are intended for cemented applications except for the 3DKNEE™ Porous Coated Femur, EMPOWR 3DKNEE™ POROUS Femur, and EMPOWR POROUS Tibia which are intended for cementless applications.
Product codes
JWH
Device Description
The EMPOWR Universal Tibial Baseplate Implant is a line extension to the EMPOWR Knee platform to include a tibial baseplate implant with accessories (stem extensions and augments) and instruments, which provide surgeons with comprehensive surgical solutions to address a variety of patient demographics and surgeon preferences.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Knee Joint
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-Clinical Testing: Testing has been performed for baseplate/stem extension fatigue testing, baseplate strength FEA, augment screw characterization, and locking mechanism disassembly. This testing has determined that the subject device is similar to the evaluated predicate device.
Endotoxin Assessment: Bacterial endotoxin testing was conducted and was found to meet the expected endotoxin limits.
Clinical Testing: Clinical testing was not required / performed.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis.
(a)
Identification. A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym and name on the right. The Department of Health & Human Services logo is a stylized depiction of a human figure, while the FDA acronym and name are written in blue, with the acronym in a square and the name in a sans-serif font.
Encore Medical, L.P. Teffany Hutto Manager, Regulatory Affairs 9800 Metric Blvd Austin, Texas 78758
March 5, 2018
Re: K173723
Trade/Device Name: EMPOWR Universal Tibial Baseplate Regulation Number: 21 CFR 888.3560 Regulation Name: Knee Joint Patellofemorotibial Polymer Semi-Constrained Cemented Prosthesis Regulatory Class: Class II Product Code: JWH Dated: December 1, 2017 Received: December 5, 2017
Dear Teffany Hutto:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
Page 2 - Teffany Hutto
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.
510(k) Number (if known) K173723
Device Name EMPOWR Universal Tibial Baseplate
Indications for Use (Describe)
Joint replacement is indicated for patients suffering from disability due to:
-
degenerative, post-traumatic or rheumatoid arthritis;
-
avascular necrosis of the femoral condyle;
-
post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.
-
moderate valgus, varus, or flexion deformities;
-
treatment of fractures that are unmanageable using other techniques.
This device may also be indicated in the salvage of previously failed surgical attempts. All devices are intended for cemented applications except for the 3DKNEE™ Porous Coated Femur, EMPOWR 3DKNEE™ POROUS Femur, and EMPOWR POROUS Tibia which are intended for cementless applications.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
Date: March 5, 2018
Manufacturer: DJO Surgical (legally Encore Medical, L.P.) 9800 Metric Blvd Austin, TX 78758
Contact Person: Teffany Hutto Manager, Regulatory Affairs Phone: (512) 834-6255 Fax: (760) 597-3466 Email: teffany.hutto@djoglobal.com
| Product | Classification | Product Code | Product Code | Regulation and Classification Name |
|---|---|---|---|---|
| EMPOWR Universal Tibial Baseplate | Class II | JWH | JWH | Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis |
| per 888.3560 |
Description:
The EMPOWR Universal Tibial Baseplate Implant is a line extension to the EMPOWR Knee platform to include a tibial baseplate implant with accessories (stem extensions and augments) and instruments, which provide surgeons with comprehensive surgical solutions to address a variety of patient demographics and surgeon preferences.
Indications for Use:
Joint replacement is indicated for patients suffering from disability due to:
- degenerative, post-traumatic or rheumatoid arthritis; .
- . avascular necrosis of the femoral condyle;
- post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, ● dysfunction or prior patellectomy;
- moderate valgus, varus or flexion deformities;
- treatment of fractures that are unmanageable using other techniques. .
This device may also be indicated in the salvage of previously failed surgical attempts. All devices are intended for cemented applications except for the 3DKNEE™ Porous Coated Femur, EMPOWR 3DKNEE™ POROUS Femur, and EMPOWR POROUS Tibia which are intended for cementless applications.
Predicate Devices:
- DJO Surgical EMPOWR Knee System K143242 ●
- DJO Surgical Foundation Modular Tibial Baseplate K932425 ●
- DJO Surgical Movation Knee K100900 ●
Comparable Features and Differences to Predicate Device(s):
| Features Exactly the
Same as Predicate to
| Subject Device | |
|---|---|
| • Size offerings | |
| • Material | |
| • Locking Mechanism geometry and surface finish of the Tibial Baseplate | |
| • Distal keel profile and surface finish | |
| • Intended Use |
4
| Features Similar as
Predicate to Subject
| Device | Stem length is the same once a modular stem plug is threaded onto the distal end of the tibial base Cement grooves on the side of the stem extension Threaded bolt assembly to distal side of tibial base implant |
|---|---|
| Features Different from | |
| Predicate to Subject | |
| Device | Stem boss height is common 25mm for all tibia sizes Size specific modular stem plug that restores the height of the tibial |
| baseplate; stem plug may be removed intra-operatively to facilitate | |
| assembly with a stem extension accessory or may be left as assembled and | |
| implanted threaded holes added to the distal (bone interface) side to use as an | |
| attachment means for a bolt to assemble augment accessories Female taper in the proximal (mating tibial insert locking mechanism) to | |
| facilitate assembly with a thicker and more constrained posterior stabilized | |
| tibial insert Threaded connection to distal side of tibial baseplate Augment accessories are stackable up to 15mm and flip-able so they may | |
| be used in either medial or lateral compartment Augment accessories have pockets and through slots to help facilitate | |
| cement flow between augments as added fixation to the tibial baseplate | |
| implant |
Non-Clinical Testing: Testing has been performed for baseplate/stem extension fatigue testing, baseplate strength FEA, augment screw characterization, and locking mechanism disassembly. This testing has determined that the subject device is similar to the evaluated predicate device.
Endotoxin Assessment: Bacterial endotoxin testing was conducted and was found to meet the expected endotoxin limits.
Clinical Testing: Clinical testing was not required / performed.
Conclusions: All testing and evaluations demonstrate that the device is substantially equivalent to the predicates identified.